A Phase 3 interventional study of Adalimumab in Juvenile Idiopathic Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 2 Years to 4 Years. Per ClinicalTrials.gov, last updated 2016-01-26.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Juvenile by AbbVie — 2 open to participants now, 3 under way, 2 of them phase 3. Arthritis, Juvenile · AbbVie.
Among the 10 studies in Arthritis, Juvenile by AbbVie, this one is the only one that started in 2009, is one of 4 in phase 3, and was the 1st registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →2 of the 10 studies in Arthritis, Juvenile by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Canada and 6 more countries
Ages 5–17
AbbVie · Sites in United States, Argentina, Australia and 14 more countries
Ages 1–17
By country, each count listing its studies:
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 4 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 46 across the 5 interventional studies, 70 across the 5 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Juvenile by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the safety of adalimumab in patients 2 to \< 4 years of age or ≥ 4 years of age weighing \< 15 kg, with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) or polyarticular course JIA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Screening laboratory and other analyses show any of the following abnormal results:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalimumab 24 mg/m\^2 body surface area (BSA) up to a total dose of 20 mg administered every other week (eow) by parent or designee as a single dose via subcutaneous injection at approximately the same time of day, for a minimum of 24 weeks. Participants could continue in the study until age 4 and 15 kg (US and Puerto Rico) or for up to 1 additional year after reaching age 4 and 15 kg (EU). Visits beyond Week 24 occurred every 12 weeks for those participants who continued in the study.
Drug: Adalimumab
Adalimumab solution for injection for subcutaneous use.
Also known as: Humira, ABT-D2E7
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. If an AE meets any of the following criteria, it is considered a serious adverse event (SAE): Results in death, is life-threatening, results in hospitalization or the prolongation of hospitalization, is a congenital anomaly or a persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent a serious outcome. A treatment-emergent AE (TEAE) is defined as any AE with onset or worsening reported by a participant from the time that the first dose of adalimumab is administered until 5 half-lives (70 days) have elapsed following discontinuation of adalimumab administration (total of 32.5 months).
Time frame: TEAEs were collected from first dose of study drug until 70 days after the last dose of study drug and before start of commercial adalimumab or other biologics (32.5 months).
Mean Serum Adalimumab Trough Concentrations at Week 0, Week 12, and Week 24
Adalimumab concentrations in serum were determined using a validated enzyme-linked immunoadsorbent assay (ELISA) method. The lower limit of quantitation (LLOQ) for adalimumab is 3.13 ng/mL.
Time frame: Weeks 0, 12, and 24
Hemoglobin: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Hematocrit: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Red Blood Cell (RBC) Count: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Platelets: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
White Blood Cell (WBC) Count: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Neutrophils: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Lymphocytes: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Monocytes: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Eosinophils: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Basophils: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Alanine Aminotransferase (SGPT/ALT): Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Aspartate Aminotransferase (SGOT/AST): Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug.Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Alkaline Phosphatase (ALP): Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Creatine Phosphokinase: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Total Bilirubin: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Creatinine: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Uric Acid: Mean Change From Baseline to Each Visit
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 30% Response (PedACR30)
The PedACR30 response is defined by the PedACR as ≥30% improvement in at least 3 of 6 JIA core set criteria, and ≥30% worsening in ≤1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with loss of passive motion \[LOM\] and joints with pain on passive motion \[POM\], tenderness, or both), number of joints with LOM, Disability Index of Child Health Assessment Questionnaire (DICHAQ), and C-reactive protein (CRP). Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using last observation carried forward (LOCF) and non-responder imputation (NRI); observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 50% Response (PedACR50)
The PedACR50 response is defined by the PedACR as ≥ 50% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 70% Response (PedACR70)
The PedACR70 response is defined by the PedACR as ≥ 70% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 90% Response (PedACR90)
The PedACR90 response is defined by the PedACR as ≥ 90% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Physician's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit
The physician's assessment of participant's overall disease activity on a visual analog scale (VAS). The VAS is a 100 mm scale, with scores ranging from 0 (very good) to 100 (very bad). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Parent's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit
The parent's assessment of how the participant's arthritis is doing overall on a VAS. The VAS is a 100 mm scale, with scores ranging from 0 (very good) to 100 (very bad). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Disability Index of Child Health Assessment Questionnaire (DICHAQ): Mean Change From Baseline to Each Visit
The DICHAQ is a self-reported participant-oriented outcome measure, calculated as the mean of the following 8 category scores (range: 0 to 3): Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The score of each category is calculated as the maximum of the scores for the questions within that category. If aids and devices and/or help from another person are used for a category, a lower category score is adjusted to 2 for that category. A participant must have scores for at least 6 categories in order to compute the DICHAQ score. Total score is derived as average of all categories: 0 (no disability) to 3 (complete disability). Baseline is the last value prior to the first dose of study drug. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Active Joint Counts (AJC73): Mean Change From Baseline to Each Visit
A joint assessment was recorded at all study visits to assess the number of active joints, with a total possible score of 0 (no active joints) to 73 (all active joints). Active joints are defined as joints with positive results for tenderness, swelling, pain on passive motion, or limitation of passive motion. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Limitation of Passive Motion (LOM69) Joint Count: Mean Change From Baseline to Each Visit
Sixty-nine joints were assessed by physical examination. The joints to be examined for LOM were the same as those examined for tenderness, except that the sacroiliac, sternoclavicular, and acromio clavicular joints were excluded. LOM of the joint was classified as present ("1"), absent ("0"), or replaced/injected ("9"). Scores range from 0 to 621, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120
C-reactive Protein (CRP): Mean Change From Baseline to Each Visit
CRP is a laboratory parameter and considered as an efficacy variable. CRP is a general marker of inflammation that is sensitive to acute changes in inflammatory response. CRP is reported using mg/dL. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Tender Joint Count (TJC75): Mean Change From Baseline to Each Visit
Seventy-five joints or regions were assessed by pressure and joint manipulation on physical examination. Joint tenderness was classified as either present ("1"), absent ("0") or replaced/injected ("9"). Scores range from 0 to 675, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Swollen Joint Count (SJC66): Mean Change From Baseline to Each Visit
Sixty-six joints were assessed by physical examination. The joints to be examined for swelling were the same as those examined for tenderness, except that the hip, subtalar, sacroiliac, lumbar spine, thoracic spine, and cervical spine joints were excluded. Joint swelling was classified as present ("1"), absent ("0") or replaced/injected ("9"). Scores range from 0 to 594, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Pain on Passive Motion (POM75) Joint Count: Mean Change From Baseline to Each Visit
Seventy-five joints were assessed by physical examination. The joints to be examined for POM were the same as those examined for tenderness. POM of the joint was classified as present ("1"), absent ("0"), or replaced/injected ("9"). Scores range from 0 to 675, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Global Health Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Physical Functioning Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120.
Child's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations/Emotional/Behavioral Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations - Physical Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Bodily Pain/Discomfort Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Behavior Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Global Behavior Item: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Mental Health Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Self Esteem Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) General Health Perceptions Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Change in Health Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Emotional Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Time Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Family Activities Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Child's Health Questionnaire Parent Form (CHQ-PF50) Family Cohesion Category: Mean Change From Baseline to Each Visit
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Participants were enrolled at 14 investigative sites in the Czech Republic, France, Germany, and the United States.
| Milestone | Adalimumab |
|---|---|
| Started | 32 |
| Completed | 26 |
| Not completed | 6 |
| Withdrew: Loss of efficacy | 2 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 1 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. If an AE meets any of the following criteria, it is considered a serious adverse event (SAE): Results in death, is life-threatening, results in hospitalization or the prolongation of hospitalization, is a congenital anomaly or a persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent a serious outcome. A treatment-emergent AE (TEAE) is defined as any AE with onset or worsening reported by a participant from the time that the first dose of adalimumab is administered until 5 half-lives (70 days) have elapsed following discontinuation of adalimumab administration (total of 32.5 months).
| participants | Adalimumab |
|---|---|
| Any Treatment-emergent AE | 29 |
| Any Treatment-emergent SAE | 5 |
Adalimumab concentrations in serum were determined using a validated enzyme-linked immunoadsorbent assay (ELISA) method. The lower limit of quantitation (LLOQ) for adalimumab is 3.13 ng/mL.
| µg/mL | Adalimumab |
|---|---|
| Week 0 | 0 ± 0 |
| Week 12 | 6.97 ± 5.69 |
| Week 24 | 7.78 ± 5.85 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| g/L | Adalimumab |
|---|---|
| Week 12 (n=29) | 6.7 ± 7.32 |
| Week 24 (n=29) | 6.7 ± 9.76 |
| Week 36 (n=25) | 5.5 ± 9.31 |
| Week 48 (n=24) | 5.3 ± 10.68 |
| Week 60 (n=21) | 6 ± 10.96 |
| Week 72 (n=17) | 9.5 ± 10.65 |
| Week 84 (n=16) | 10.5 ± 13.69 |
| Week 96 (n=11) | 8.6 ± 9.99 |
| Week 108 (n=9) | 7.7 ± 8.08 |
| Week 120 (n=3) | 4.7 ± 2.89 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| Fraction | Adalimumab |
|---|---|
| Week 12 (n=29) | 0.018 ± 0.0206 |
| Week 24 (n=29) | 0.016 ± 0.0289 |
| Week 36 (n=25) | 0.017 ± 0.0292 |
| Week 48 (n=24) | 0.011 ± 0.0288 |
| Week 60 (n=21) | 0.009 ± 0.0275 |
| Week 72 (n=17) | 0.024 ± 0.0264 |
| Week 84 (n=16) | 0.026 ± 0.0366 |
| Week 96 (n=11) | 0.023 ± 0.0319 |
| Week 108 (n=9) | 0.018 ± 0.0273 |
| Week 120 (n=3) | 0.008 ± 0.0082 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| x10˄12/L | Adalimumab |
|---|---|
| Week 12 (n=29) | 0.15 ± 0.231 |
| Week 24 (n=29) | 0.08 ± 0.308 |
| Week 36 (n=25) | 0.098 ± 0.277 |
| Week 48 (n=24) | 0.05 ± 0.213 |
| Week 60 (n=21) | 0.07 ± 0.296 |
| Week 72 (n=17) | 0.1 ± 0.187 |
| Week 84 (n=16) | 0.06 ± 0.228 |
| Week 96 (n=11) | 0.08 ± 0.343 |
| Week 108 (n=9) | 0.1 ± 0.32 |
| Week 120 (n=3) | 0.03 ± 0.153 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| x10˄9/L | Adalimumab |
|---|---|
| Week 12 (n=29) | -35 ± 145.44 |
| Week 24 (n=29) | -57.7 ± 140.82 |
| Week 36 (n=25) | -75.2 ± 148.51 |
| Week 48 (n=23) | -21 ± 174.17 |
| Week 60 (n=21) | -46.7 ± 125.71 |
| Week 72 (n=17) | -51.1 ± 111.11 |
| Week 84 (n=15) | -58.5 ± 127.29 |
| Week 96 (n=11) | -49.2 ± 142.73 |
| Week 108 (n=9) | -30.4 ± 137.84 |
| Week 120 (n=3) | 20 ± 185.95 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| x10^9/L | Adalimumab |
|---|---|
| Week 12 (n=29) | 0.19 ± 3.959 |
| Week 24 (n=29) | -0.25 ± 3.756 |
| Week 36 (n=25) | -0.42 ± 4.632 |
| Week 48 (n=24) | 0.3 ± 4.804 |
| Week 60 (n=21) | 0.25 ± 2.183 |
| Week 72 (n=17) | 0.66 ± 3.225 |
| Week 84 (n=16) | 0.18 ± 2.944 |
| Week 96 (n=11) | 0.55 ± 2.757 |
| Week 108 (n=9) | -0.76 ± 4.166 |
| Week 120 (n=3) | 1.8 ± 3.651 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| x10˄9/L | Adalimumab |
|---|---|
| Week 12 (n=29) | -0.138 ± 2.9819 |
| Week 24 (n=29) | -0.619 ± 3.0082 |
| Week 36 (n=25) | -0.586 ± 3.7363 |
| Week 48 (n=24) | 0.065 ± 3.4433 |
| Week 60 (n=21) | 0.222 ± 2.0937 |
| Week 72 (n=17) | -0.169 ± 2.6167 |
| Week 84 (n=16) | -0.206 ± 2.0077 |
| Week 96 (n=11) | 0.293 ± 2.511 |
| Week 108 (n=9) | -0.39 ± 3.1702 |
| Week 120 (n=3) | 2.47 ± 3.2658 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| x10˄9/L | Adalimumab |
|---|---|
| Week 12 (n=29) | 0.371 ± 2.3523 |
| Week 24 (n=29) | 0.292 ± 1.9345 |
| Week 36 (n=25) | 0.176 ± 1.962 |
| Week 48 (n=24) | 0.186 ± 1.9584 |
| Week 60 (n=21) | -0.034 ± 1.6129 |
| Week 72 (n=17) | 0.636 ± 1.7404 |
| Week 84 (n=16) | 0.306 ± 1.5143 |
| Week 96 (n=11) | 0.006 ± 1.9402 |
| Week 108 (n=9) | -0.46 ± 2.4315 |
| Week 120 (n=3) | -0.67 ± 1.8041 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| x10^9/L | Adalimumab |
|---|---|
| Week 12 (n=29) | -0.032 ± 0.3051 |
| Week 24 (n=29) | 0.081 ± 0.4547 |
| Week 36 (n=25) | 0.028 ± 0.2978 |
| Week 48 (n=24) | -0.006 ± 0.2718 |
| Week 60 (n=21) | 0.08 ± 0.1831 |
| Week 72 (n=17) | 0.113 ± 0.2054 |
| Week 84 (n=16) | 0.061 ± 0.2594 |
| Week 96 (n=11) | 0.089 ± 0.2295 |
| Week 108 (n=9) | 0.096 ± 0.3248 |
| Week 120 (n=3) | 0.057 ± 0.0777 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| x10^9/L | Adalimumab |
|---|---|
| Week 12 (n=29) | -0.004 ± 0.1771 |
| Week 24 (n=29) | -0.006 ± 0.1545 |
| Week 36 (n=25) | -0.052 ± 0.1374 |
| Week 48 (n=24) | 0.056 ± 0.2773 |
| Week 60 (n=21) | -0.015 ± 0.1363 |
| Week 72 (n=17) | 0.069 ± 0.1886 |
| Week 84 (n=16) | 0.016 ± 0.1631 |
| Week 96 (n=11) | 0.158 ± 0.3207 |
| Week 108 (n=9) | -0.002 ± 0.0864 |
| Week 120 (n=3) | -0.063 ± 0.0929 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| x10^9/L | Adalimumab |
|---|---|
| Week 12 (n=29) | -0.012 ± 0.0299 |
| Week 24 (n=29) | -0.002 ± 0.0272 |
| Week 36 (n=25) | 0.003 ± 0.0244 |
| Week 48 (n=24) | 0.005 ± 0.0412 |
| Week 60 (n=21) | -0.003 ± 0.0256 |
| Week 72 (n=17) | 0.007 ± 0.031 |
| Week 84 (n=16) | -0.001 ± 0.0171 |
| Week 96 (n=11) | -0.003 ± 0.0205 |
| Week 108 (n=9) | -0.001 ± 0.0117 |
| Week 120 (n=3) | 0.003 ± 0.0306 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| U/L | Adalimumab |
|---|---|
| Week 12 (n=27) | 0.5 ± 9.96 |
| Week 24 (n=28) | -1.1 ± 17.13 |
| Week 36 (n=25) | 0 ± 29.82 |
| Week 48 (n=24) | -4.5 ± 24.81 |
| Week 60 (n=21) | -2 ± 10.25 |
| Week 72 (n=16) | -1.8 ± 10.1 |
| Week 84 (n=16) | -0.5 ± 14.56 |
| Week 96 (n=11) | -3.9 ± 15.4 |
| Week 108 (n=9) | -2.4 ± 6.31 |
| Week 120 (n=3) | -14.3 ± 23.12 |
Baseline is the last value prior to the first dose of study drug.Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| U/L | Adalimumab |
|---|---|
| Week 12 (n=26) | 2.8 ± 7.56 |
| Week 24 (n=28) | -0.6 ± 8.82 |
| Week 36 (n=25) | 2 ± 23.26 |
| Week 48 (n=24) | -0.7 ± 16.13 |
| Week 60 (n=21) | -0.4 ± 7.63 |
| Week 72 (n=16) | 0.3 ± 7.36 |
| Week 84 (n=16) | -0.4 ± 6.89 |
| Week 96 (n=10) | 1.5 ± 11.48 |
| Week 108 (n=9) | 0.4 ± 6.21 |
| Week 120 (n=3) | -8.3 ± 11.93 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| U/L | Adalimumab |
|---|---|
| Week 12 (n=27) | 15.7 ± 64.65 |
| Week 24 (n=28) | 10.6 ± 68.75 |
| Week 36 (n=25) | 23.2 ± 73.28 |
| Week 48 (n=24) | 21.7 ± 73.03 |
| Week 60 (n=21) | 17.9 ± 85.55 |
| Week 72 (n=16) | 17.9 ± 83.52 |
| Week 84 (n=16) | 31.5 ± 89.3 |
| Week 96 (n=11) | 59.4 ± 57.65 |
| Week 108 (n=9) | -6.3 ± 100.72 |
| Week 120 (n=3) | -72.3 ± 169.19 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| U/L | Adalimumab |
|---|---|
| Week 12 (n=27) | 17.2 ± 50.48 |
| Week 24 (n=27) | 7 ± 30.79 |
| Week 36 (n=25) | 24.8 ± 44.5 |
| Week 48 (n=24) | 18.4 ± 54.02 |
| Week 60 (n=21) | 26.6 ± 65.48 |
| Week 72 (n=16) | 41.6 ± 40.63 |
| Week 84 (n=16) | 36.4 ± 53.64 |
| Week 96 (n=11) | 28.7 ± 41.79 |
| Week 108 (n=9) | 7.2 ± 22.97 |
| Week 120 (n=3) | 14 ± 40.73 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| µmol/L | Adalimumab |
|---|---|
| Week 12 (n=27) | 1.2 ± 2.42 |
| Week 24 (n=28) | 0.6 ± 1.59 |
| Week 36 (n=25) | 0.6 ± 1.61 |
| Week 48 (n=24) | 0.9 ± 2.4 |
| Week 60 (n=21) | 1 ± 2.09 |
| Week 72 (n=16) | 0.2 ± 1.25 |
| Week 84 (n=16) | 0.5 ± 2.36 |
| Week 96 (n=11) | 0.7 ± 1.62 |
| Week 108 (n=9) | 1.1 ± 2.71 |
| Week 120 (n=3) | 2.3 ± 0.58 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| µmol/L | Adalimumab |
|---|---|
| Week 12 (n=27) | 1.7 ± 5.98 |
| Week 24 (n=28) | 0.5 ± 5.3 |
| Week 36 (n=25) | 0.3 ± 5.84 |
| Week 48 (n=24) | 2.5 ± 7.8 |
| Week 60 (n=21) | 2.8 ± 5.79 |
| Week 72 (n=16) | 3.4 ± 6.96 |
| Week 84 (n=16) | 4 ± 6.37 |
| Week 96 (n=11) | 3.2 ± 5.53 |
| Week 108 (n=9) | 6.2 ± 6.7 |
| Week 120 (n=3) | 8.7 ± 5.51 |
Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.
| µmol/L | Adalimumab |
|---|---|
| Week 12 (n=27) | 1.7 ± 48.24 |
| Week 24 (n=27) | 6.5 ± 47.93 |
| Week 36 (n=25) | 2.5 ± 41.77 |
| Week 48 (n=24) | 5.6 ± 45.62 |
| Week 60 (n=21) | 1.9 ± 30.86 |
| Week 72 (n=16) | -0.9 ± 43.53 |
| Week 84 (n=16) | -4.5 ± 46.76 |
| Week 96 (n=11) | 13.3 ± 36.39 |
| Week 108 (n=9) | -10.1 ± 33.55 |
| Week 120 (n=3) | -7 ± 27.78 |
The PedACR30 response is defined by the PedACR as ≥30% improvement in at least 3 of 6 JIA core set criteria, and ≥30% worsening in ≤1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with loss of passive motion \[LOM\] and joints with pain on passive motion \[POM\], tenderness, or both), number of joints with LOM, Disability Index of Child Health Assessment Questionnaire (DICHAQ), and C-reactive protein (CRP). Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using last observation carried forward (LOCF) and non-responder imputation (NRI); observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.
| percentage of participants | Adalimumab |
|---|---|
| Week 12 Observed (n=31) | 93.5 |
| Week 12 NRI (n=32) | 90.6 |
| Week 12 LOCF (n=31) | 93.5 |
| Week 24 Observed (n=30) | 90 |
| Week 24 NRI (n=32) | 84.4 |
| Week 24 LOCF (n=31) | 90.3 |
| Week 36 Observed (n=27) | 92.6 |
| Week 36 NRI (n=32) | 78.1 |
| Week 36 LOCF (n=31) | 93.5 |
| Week 48 Observed (n=24) | 83.3 |
| Week 48 NRI (n=32) | 62.5 |
| Week 48 LOCF (n=31) | 83.9 |
| Week 60 Observed (n=20) | 90 |
| Week 60 NRI (n=32) | 56.3 |
| Week 60 LOCF (n=31) | 87.1 |
| Week 72 Observed (n=17) | 100 |
| Week 84 Observed (n=17) | 100 |
| Week 96 Observed (n=13) | 92.3 |
| Week 108 Observed (n=9) | 88.9 |
| Week 120 Observed (n=3) | 100 |
The PedACR50 response is defined by the PedACR as ≥ 50% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.
| percentage of participants | Adalimumab |
|---|---|
| Week 12 Observed (n=31) | 90.3 |
| Week 12 NRI (n=32) | 87.5 |
| Week 12 LOCF (n=31) | 90.3 |
| Week 24 Observed (n=30) | 83.3 |
| Week 24 NRI (n=32) | 78.1 |
| Week 24 LOCF (n=31) | 83.9 |
| Week 36 Observed (n=27) | 88.9 |
| Week 36 NRI (n=32) | 75 |
| Week 36 LOCF (n=31) | 90.3 |
| Week 48 Observed (n=24) | 79.2 |
| Week 48 NRI (n=32) | 59.4 |
| Week 48 LOCF (n=31) | 80.6 |
| Week 60 Observed (n=20) | 80 |
| Week 60 NRI (n=32) | 50 |
| Week 60 LOCF (n=31) | 80.6 |
| Week 72 Observed (n=17) | 100 |
| Week 84 Observed (n=17) | 94.1 |
| Week 96 Observed (n=13) | 92.3 |
| Week 108 Observed (n=9) | 88.9 |
| Week 120 Observed (n=3) | 100 |
The PedACR70 response is defined by the PedACR as ≥ 70% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.
| percentage of participants | Adalimumab |
|---|---|
| Week 12 Observed (n=31) | 61.3 |
| Week 12 NRI (n=32) | 59.4 |
| Week 12 LOCF (n=31) | 61.3 |
| Week 24 Observed (n=30) | 73.3 |
| Week 24 NRI (n=32) | 68.8 |
| Week 24 LOCF (n=31) | 74.2 |
| Week 36 Observed (n=27) | 66.7 |
| Week 36 NRI (n=32) | 56.3 |
| Week 36 LOCF (n=31) | 67.7 |
| Week 48 Observed (n=24) | 75 |
| Week 48 NRI (n=32) | 56.3 |
| Week 48 LOCF (n=31) | 74.2 |
| Week 60 Observed (n=20) | 70 |
| Week 60 NRI (n=32) | 43.8 |
| Week 60 LOCF (n=31) | 71 |
| Week 72 Observed (n=17) | 76.5 |
| Week 84 Observed (n=17) | 82.4 |
| Week 96 Observed (n=13) | 76.9 |
| Week 108 Observed (n=9) | 77.8 |
| Week 120 Observed (n=3) | 100 |
The PedACR90 response is defined by the PedACR as ≥ 90% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.
| percentage of participants | Adalimumab |
|---|---|
| Week 12 Observed (n=31) | 38.7 |
| Week 12 NRI (n=32) | 37.5 |
| Week 12 LOCF (n=31) | 38.7 |
| Week 24 Observed (n=30) | 36.7 |
| Week 24 NRI (n=32) | 34.4 |
| Week 24 LOCF (n=31) | 35.5 |
| Week 36 Observed (n=27) | 51.9 |
| Week 36 NRI (n=32) | 43.8 |
| Week 36 LOCF (n=31) | 51.6 |
| Week 48 Observed (n=24) | 62.5 |
| Week 48 NRI (n=32) | 46.9 |
| Week 48 LOCF (n=31) | 58.1 |
| Week 60 Observed (n=20) | 50 |
| Week 60 NRI (n=32) | 31.3 |
| Week 60 LOCF (n=31) | 51.6 |
| Week 72 Observed (n=17) | 64.7 |
| Week 84 Observed (n=17) | 64.7 |
| Week 96 Observed (n=13) | 61.5 |
| Week 108 Observed (n=9) | 66.7 |
| Week 120 Observed (n=3) | 100 |
The physician's assessment of participant's overall disease activity on a visual analog scale (VAS). The VAS is a 100 mm scale, with scores ranging from 0 (very good) to 100 (very bad). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=31) | -41.4 ± 21.2 |
| Week 24 (n=30) | -45.3 ± 21.32 |
| Week 36 (n=28) | -43 ± 23.9 |
| Week 48 (n=24) | -46.5 ± 18.35 |
| Week 60 (n=21) | -42.7 ± 28.17 |
| Week 72 (n=17) | -51.1 ± 19.53 |
| Week 84 (n=17) | -50.5 ± 16.77 |
| Week 96 (n=13) | -47.5 ± 24.42 |
| Week 108 (n=9) | -48.3 ± 28.24 |
| Week 120 (n=3) | -56.3 ± 5.13 |
The parent's assessment of how the participant's arthritis is doing overall on a VAS. The VAS is a 100 mm scale, with scores ranging from 0 (very good) to 100 (very bad). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=31) | -28.1 ± 29.91 |
| Week 24 (n=30) | -32.2 ± 29.74 |
| Week 36 (n=27) | -35.1 ± 27.42 |
| Week 48 (n=24) | -35.6 ± 32.19 |
| Week 60 (n=21) | -34.5 ± 33.31 |
| Week 72 (n=17) | -43.8 ± 25.58 |
| Week 84 (n=17) | -42.6 ± 28.62 |
| Week 96 (n=13) | -45.8 ± 29.1 |
| Week 108 (n=9) | -39.9 ± 37.54 |
| Week 120 (n=3) | -47.7 ± 34.96 |
The DICHAQ is a self-reported participant-oriented outcome measure, calculated as the mean of the following 8 category scores (range: 0 to 3): Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The score of each category is calculated as the maximum of the scores for the questions within that category. If aids and devices and/or help from another person are used for a category, a lower category score is adjusted to 2 for that category. A participant must have scores for at least 6 categories in order to compute the DICHAQ score. Total score is derived as average of all categories: 0 (no disability) to 3 (complete disability). Baseline is the last value prior to the first dose of study drug. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=31) | -0.5 ± 0.64 |
| Week 24 (n=30) | -0.5 ± 0.69 |
| Week 36 (n=27) | -0.6 ± 0.7 |
| Week 48 (n=24) | -0.6 ± 0.68 |
| Week 60 (n=21) | -0.6 ± 0.71 |
| Week 72 (n=16) | -0.9 ± 0.64 |
| Week 84 (n=17) | -0.9 ± 0.68 |
| Week 96 (n=13) | -0.8 ± 0.56 |
| Week 108 (n=9) | -0.8 ± 0.63 |
| Week 120 (n=3) | -0.8 ± 1.09 |
A joint assessment was recorded at all study visits to assess the number of active joints, with a total possible score of 0 (no active joints) to 73 (all active joints). Active joints are defined as joints with positive results for tenderness, swelling, pain on passive motion, or limitation of passive motion. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 2 (n=32) | -5 ± 6.58 |
| Week 4 (n=32) | -6.1 ± 6.69 |
| Week 8 (n=32) | -7 ± 5.24 |
| Week 12 (n=31) | -7.3 ± 4.52 |
| Week 16 (n=31) | -7.1 ± 5.87 |
| Week 20 (n=29) | -8 ± 5.68 |
| Week 24 (n=30) | -7.2 ± 5.6 |
| Week 36 (n=28) | -7.3 ± 5.21 |
| Week 48 (n=24) | -8 ± 5.5 |
| Week 60 (n=20) | -9.5 ± 7.5 |
| Week 72 (n=17) | -10.2 ± 6.64 |
| Week 84 (n=17) | -10.4 ± 7.57 |
| Week 96 (n=13) | -8.9 ± 7.04 |
| Week 108 (n=9) | -5.9 ± 3.33 |
| Week 120 (n=3) | -7.3 ± 2.08 |
Sixty-nine joints were assessed by physical examination. The joints to be examined for LOM were the same as those examined for tenderness, except that the sacroiliac, sternoclavicular, and acromio clavicular joints were excluded. LOM of the joint was classified as present ("1"), absent ("0"), or replaced/injected ("9"). Scores range from 0 to 621, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 2 (n=32) | -4.5 ± 7.14 |
| Week 4 (n=32) | -5.4 ± 6.48 |
| Week 8 (n=32) | -5.3 ± 5.02 |
| Week 12 (n=31) | -5.6 ± 4.8 |
| Week 16 (n=31) | -6.3 ± 6.31 |
| Week 20 (n=29) | -6.8 ± 6.63 |
| Week 24 (n=30) | -5.6 ± 5.54 |
| Week 36 (n=28) | -5.1 ± 5.29 |
| Week 48 (n=24) | -5.5 ± 7.06 |
| Week 60 (n=20) | -5.5 ± 8.31 |
| Week 72 (n=17) | -6.9 ± 7.84 |
| Week 84 (n=17) | -8.4 ± 6.9 |
| Week 96 (n=13) | -7.5 ± 6.73 |
| Week 108 (n=9) | -5.2 ± 3.96 |
| Week 120 (n=3) | -6 ± 2.65 |
CRP is a laboratory parameter and considered as an efficacy variable. CRP is a general marker of inflammation that is sensitive to acute changes in inflammatory response. CRP is reported using mg/dL. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| mg/dL | Adalimumab |
|---|---|
| Week 12 (n=28) | -0.6 ± 2.65 |
| Week 24 (n=28) | -0.2 ± 3.2 |
| Week 36 (n=25) | -0.4 ± 3.08 |
| Week 48 (n=23) | 0.4 ± 2.68 |
| Week 60 (n=20) | -0.3 ± 1.83 |
| Week 72 (n=17) | -0.7 ± 1.25 |
| Week 84 (n=17) | -0.7 ± 1.47 |
| Week 96 (n=12) | 0.1 ± 1.6 |
| Week 108 (n=9) | 0.2 ± 1.93 |
| Week 120 (n=3) | 0.3 ± 0.28 |
Seventy-five joints or regions were assessed by pressure and joint manipulation on physical examination. Joint tenderness was classified as either present ("1"), absent ("0") or replaced/injected ("9"). Scores range from 0 to 675, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 2 (n=32) | -2.3 ± 4.62 |
| Week 4 (n=32) | -2.8 ± 4.48 |
| Week 8 (n=32) | -3.1 ± 4.31 |
| Week 12 (n=31) | -2.7 ± 5.09 |
| Week 16 (n=31) | -3.5 ± 4.77 |
| Week 20 (n=29) | -3.9 ± 5.09 |
| Week 24 (n=30) | -3 ± 5.54 |
| Week 36 (n=28) | -2.9 ± 5.65 |
| Week 48 (n=24) | -4.4 ± 4.85 |
| Week 60 (n=20) | -4.5 ± 5.85 |
| Week 72 (n=17) | -5.3 ± 5.53 |
| Week 84 (n=17) | -4.8 ± 5.2 |
| Week 96 (n=13) | -4 ± 5.46 |
| Week 108 (n=9) | -1.1 ± 4.73 |
| Week 120 (n=3) | -1.3 ± 2.31 |
Sixty-six joints were assessed by physical examination. The joints to be examined for swelling were the same as those examined for tenderness, except that the hip, subtalar, sacroiliac, lumbar spine, thoracic spine, and cervical spine joints were excluded. Joint swelling was classified as present ("1"), absent ("0") or replaced/injected ("9"). Scores range from 0 to 594, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 2 (n=32) | -4.5 ± 6.46 |
| Week 4 (n=32) | -5.3 ± 6.63 |
| Week 8 (n=32) | -6 ± 5.32 |
| Week 12 (n=31) | -6.2 ± 4.24 |
| Week 16 (n=31) | -6.1 ± 6.59 |
| Week 20 (n=29) | -6.9 ± 5.62 |
| Week 24 (n=30) | -6.3 ± 5.83 |
| Week 36 (n=28) | -6.2 ± 4.73 |
| Week 48 (n=24) | -6.7 ± 5.34 |
| Week 60 (n=20) | -8.4 ± 7.15 |
| Week 72 (n=17) | -8.9 ± 6.06 |
| Week 84 (n=17) | -9.4 ± 7.15 |
| Week 96 (n=13) | -8.5 ± 6.89 |
| Week 108 (n=9) | -5.8 ± 3.31 |
| Week 120 (n=3) | -7.3 ± 2.08 |
Seventy-five joints were assessed by physical examination. The joints to be examined for POM were the same as those examined for tenderness. POM of the joint was classified as present ("1"), absent ("0"), or replaced/injected ("9"). Scores range from 0 to 675, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 2 (n=32) | -3.3 ± 4.5 |
| Week 4 (n=32) | -4 ± 4.01 |
| Week 8 (n=32) | -4.6 ± 5.17 |
| Week 12 (n=31) | -4.9 ± 4.59 |
| Week 16 (n=31) | -4.9 ± 4.6 |
| Week 20 (n=29) | -5.4 ± 4.81 |
| Week 24 (n=30) | -4.1 ± 7.32 |
| Week 36 (n=28) | -4.3 ± 7.34 |
| Week 48 (n=24) | -5.8 ± 4.42 |
| Week 60 (n=20) | -5.9 ± 5.25 |
| Week 72 (n=17) | -6.4 ± 5.41 |
| Week 84 (n=17) | -6.1 ± 5.34 |
| Week 96 (n=13) | 5.7 ± 5.12 |
| Week 108 (n=9) | -3.6 ± 5.85 |
| Week 120 (n=3) | -5.3 ± 1.53 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=29) | 17.1 ± 29.48 |
| Week 24 (n=28) | 24.3 ± 25.77 |
| Week 36 (n=24) | 25 ± 27.27 |
| Week 48 (n=22) | 30.9 ± 23.79 |
| Week 60 (n=19) | 21.8 ± 27.35 |
| Week 72 (n=17) | 31.5 ± 24.86 |
| Week 84 (n=17) | 26.2 ± 25.89 |
| Week 96 (n=11) | 32.7 ± 20.66 |
| Week 108 (n=8) | 36.9 ± 19.99 |
| Week 120 (n=3) | 45 ± 17.32 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=31) | 30.6 ± 32.14 |
| Week 24 (n=30) | 31.6 ± 31.91 |
| Week 36 (n=27) | 36.4 ± 31.26 |
| Week 48 (n=23) | 31.5 ± 28.39 |
| Week 60 (n=21) | 29 ± 32.3 |
| Week 72 (n=16) | 40.6 ± 27 |
| Week 84 (n=17) | 40 ± 30.44 |
| Week 96 (n=13) | 34.3 ± 27.88 |
| Week 108 (n=9) | 37 ± 27.92 |
| Week 120 (n=3) | 53.7 ± 8.49 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=23) | 20.8 ± 32.53 |
| Week 24 (n=22) | 17.7 ± 29.43 |
| Week 36 (n=20) | 17.2 ± 25.86 |
| Week 48 (n=18) | 16 ± 27.28 |
| Week 60 (n=16) | 20.8 ± 31.91 |
| Week 72 (n=13) | 26.5 ± 32.25 |
| Week 84 (n=13) | 20.5 ± 33.29 |
| Week 96 (n=9) | 30.9 ± 32.76 |
| Week 108 (n=7) | 23.8 ± 25.2 |
| Week 120 (n=2) | 33.3 ± 47.14 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=21) | 28.6 ± 32.97 |
| Week 24 (n=20) | 31.7 ± 35 |
| Week 36 (n=18) | 30.6 ± 39.3 |
| Week 48 (n=17) | 27.5 ± 37.24 |
| Week 60 (n=15) | 34.4 ± 39.07 |
| Week 72 (n=12) | 36.1 ± 41.34 |
| Week 84 (n=12) | 34.7 ± 43.5 |
| Week 96 (n=8) | 41.7 ± 37.8 |
| Week 108 (n=6) | 47.2 ± 37.14 |
| Week 120 (n=1) | 66.7 ± 0 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=30) | 35 ± 30.6 |
| Week 24 (n=29) | 36.2 ± 32.99 |
| Week 36 (n=26) | 38.8 ± 27.76 |
| Week 48 (n=23) | 41.7 ± 29.64 |
| Week 60 (n=20) | 39 ± 34.78 |
| Week 72 (n=17) | 48.2 ± 20.38 |
| Week 84 (n=17) | 41.2 ± 25.47 |
| Week 96 (n=13) | 42.3 ± 23.51 |
| Week 108 (n=9) | 41.1 ± 37.56 |
| Week 120 (n=3) | 50 ± 17.32 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=29) | 5.6 ± 15.78 |
| Week 24 (n=28) | 4.2 ± 13.58 |
| Week 36 (n=27) | 0.4 ± 16.87 |
| Week 48 (n=24) | 3.6 ± 17.04 |
| Week 60 (n=21) | -0.3 ± 13.95 |
| Week 72 (n=17) | 0.1 ± 16.44 |
| Week 84 (n=17) | 1.5 ± 13.97 |
| Week 96 (n=13) | 7.1 ± 11.81 |
| Week 108 (n=9) | 8.9 ± 10.46 |
| Week 120 (n=3) | -6.1 ± 31.28 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=19) | 4.5 ± 18.17 |
| Week 24 (n=19) | 10.8 ± 17.66 |
| Week 36 (n=18) | 9.2 ± 25.04 |
| Week 48 (n=16) | 4.1 ± 18.55 |
| Week 60 (n=13) | -3.5 ± 20.35 |
| Week 72 (n=10) | 2 ± 15.31 |
| Week 84 (n=11) | -5 ± 14.32 |
| Week 96 (n=9) | 0 ± 17.68 |
| Week 108 (n=6) | -4.2 ± 10.21 |
| Week 120 (n=1) | -25 ± 0 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=31) | 3.5 ± 11.12 |
| Week 24 (n=30) | 3.5 ± 10.76 |
| Week 36 (n=27) | 4.1 ± 14.01 |
| Week 48 (n=24) | 5.4 ± 11.88 |
| Week 60 (n=21) | 2.1 ± 14.02 |
| Week 72 (n=17) | 5 ± 12.37 |
| Week 84 (n=17) | 2.6 ± 8.5 |
| Week 96 (n=13) | 4.2 ± 11.88 |
| Week 108 (n=9) | -0.8 ± 15 |
| Week 120 (n=3) | -3.3 ± 20.21 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=23) | 10.6 ± 23.91 |
| Week 24 (n=22) | 10.5 ± 24.75 |
| Week 36 (n=19) | 16.8 ± 22.02 |
| Week 48 (n=16) | 15.2 ± 22.6 |
| Week 60 (n=14) | 10.2 ± 22.53 |
| Week 72 (n=13) | -2.8 ± 31.78 |
| Week 84 (n=13) | 9.4 ± 18.52 |
| Week 96 (n=9) | 6.9 ± 19.87 |
| Week 108 (n=6) | -4.2 ± 10.87 |
| Week 120 (n=1) | 4.2 ± 0 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=26) | 0.7 ± 14.27 |
| Week 24 (n=25) | 3.8 ± 14.98 |
| Week 36 (n=22) | 6.2 ± 15.99 |
| Week 48 (n=19) | 7.2 ± 13.36 |
| Week 60 (n=18) | 0.7 ± 10.65 |
| Week 72 (n=15) | 9.1 ± 10.1 |
| Week 84 (n=15) | 7.2 ± 13.03 |
| Week 96 (n=11) | 10.9 ± 16 |
| Week 108 (n=7) | 9 ± 16.61 |
| Week 120 (n=3) | 4.7 ± 12.92 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=30) | 1.4 ± 1.75 |
| Week 24 (n=29) | 1.7 ± 1.67 |
| Week 36 (n=25) | 1.7 ± 1.8 |
| Week 48 (n=22) | 1.7 ± 2.4 |
| Week 60 (n=20) | 1.3 ± 2.57 |
| Week 72 (n=16) | 1.6 ± 2.13 |
| Week 84(n=16) | 1.3 ± 1.98 |
| Week 96 (n=12) | 1.5 ± 2.02 |
| Week 108 (n=8) | 0.9 ± 2.7 |
| Week 120 (n=3) | 2.3 ± 0.58 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=30) | 11.4 ± 26.12 |
| Week 24 (n=28) | 19 ± 28.59 |
| Week 36 (n=26) | 29.2 ± 33.1 |
| Week 48 (n=23) | 34.1 ± 33.98 |
| Week 60 (n=20) | 31.7 ± 32.4 |
| Week 72 (n=16) | 34.4 ± 36.37 |
| Week 84 (n=16) | 27.6 ± 41.69 |
| Week 96 (n=11) | 43.9 ± 40.15 |
| Week 108 (n=8) | 46.9 ± 40.81 |
| Week 120 (n=2) | 62.5 ± 41.25 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=30) | 4.6 ± 24.5 |
| Week 24 (n=28) | 13.5 ± 28.59 |
| Week 36 (n=26) | 21.8 ± 24.24 |
| Week 48 (n=23) | 18.4 ± 24.76 |
| Week 60 (n=20) | 13.3 ± 31.55 |
| Week 72 (n=16) | 22.2 ± 30.09 |
| Week 84 (n=16) | 17.4 ± 35.13 |
| Week 96 (n=12) | 20.4 ± 27.15 |
| Week 108 (n=8) | 15.3 ± 25.85 |
| Week 120 (n=2) | 55.6 ± 62.85 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=30) | 8.3 ± 28.41 |
| Week 24 (n=28) | 17.6 ± 24.15 |
| Week 36 (n=26) | 20 ± 28.5 |
| Week 48 (n=23) | 16.8 ± 26.43 |
| Week 60 (n=20) | 14.8 ± 30.9 |
| Week 72 (n=16) | 17.2 ± 31.43 |
| Week 84 (n=16) | 18.2 ± 30.27 |
| Week 96 (n=12) | 19.4 ± 27.6 |
| Week 108 (n=8) | 20.8 ± 29.38 |
| Week 120 (n=2) | 68.8 ± 20.62 |
The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.
| units on a scale | Adalimumab |
|---|---|
| Week 12 (n=30) | 2.5 ± 14 |
| Week 24 (n=28) | 4.3 ± 23.28 |
| Week 36 (n=26) | 5.6 ± 20.66 |
| Week 48 (n=23) | 3.7 ± 15.61 |
| Week 60 (n=20) | 4.8 ± 16.66 |
| Week 72 (n=16) | 7.2 ± 29.15 |
| Week 84 (n=16) | 8.4 ± 39.19 |
| Week 96 (n=12) | 18.8 ± 35.36 |
| Week 108 (n=8) | 19.4 ± 35.3 |
| Week 120 (n=2) | -27.5 ± 38.89 |
Collected over TEAEs were collected from first dose of study drug until 70 days after the last dose of study drug and before start of commercial adalimumab or other biologics (32.5 months); SAEs were collected from the time informed consent was obtained (33.5 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab | — | 5/32 (15.6%) | 27/32 (84.4%) |
| Event | Adalimumab |
|---|---|
| Dental cariesGastrointestinal disorders | 1/32 |
| Juvenile arthritisMusculoskeletal and connective tissue disorders | 1/32 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 1/32 |
| Gastroenteritis rotavirusInfections and infestations | 1/32 |
| VaricellaInfections and infestations | 1/32 |
| Event | Adalimumab |
|---|---|
| NasopharyngitisInfections and infestations | 8/32 |
| PyrexiaGeneral disorders | 7/32 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/32 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 6/32 |
| BronchitisInfections and infestations | 6/32 |
| Upper respiratory tract infectionInfections and infestations | 6/32 |
| VomitingGastrointestinal disorders | 5/32 |
| Otitis mediaInfections and infestations | 5/32 |
| DiarrhoeaGastrointestinal disorders | 4/32 |
| RashSkin and subcutaneous tissue disorders | 4/32 |
| Age, Continuous(years) | Adalimumab |
|---|---|
| Mean | 3.04 ± 0.723 |
| Age, Customized(participants) | Adalimumab |
|---|---|
| < 4 years | 28 |
| ≥ 4 years | 4 |
| Sex: Female, Male(Participants) | Adalimumab |
|---|---|
| Female | 28 |
| Male | 4 |
No study locations are listed for this record.
The record gives a start of Mar 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →